- Home
- MGNX vs NPCT Comparison
MGNX vs NPCT Comparison
Compare MGNX & NPCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MGNX | NPCT |
|---|---|---|
| Founded | 2000 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 256.8M | 286.7M |
| IPO Year | 2013 | N/A |
Fundamental Metrics
Financial Performance| Metric | MGNX | NPCT |
|---|---|---|
| Price | $4.09 | $9.66 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 479.2K | 100.2K |
| Earning Date | 05-08-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 9.82% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $149,500,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.19 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.30 | $9.62 |
| 52 Week High | $5.08 | $11.12 |
Technical Indicators
Market Signals| Indicator | MGNX | NPCT |
|---|---|---|
| Relative Strength Index (RSI) | 48.54 | 40.19 |
| Support Level | $3.80 | $9.65 |
| Resistance Level | $4.38 | $9.89 |
| Average True Range (ATR) | 0.19 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 48.65 | 18.15 |
Price Performance
Historical ComparisonAbout MGNX MacroGenics Inc.
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
About NPCT Nuveen Core Plus Impact Fund of Beneficial Interest
Nuveen Core Plus Impact Fund is an organized, diversified, closed-end management investment company. The Fund's investment objective is to provide a high level of current income.